GLG News by Council Members who Purchase the Da Vinci Robotic System

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Provenge - Do we really have a choice?

November 19, 2010

Medicare Panel Supports Use of Provenge in FDA-Approved Population | blogs.wsj.com

Provenge has received FDA clearance for the use in hormone resistant prostate cancer, a disease that kills over 30,000 American men each year. The data says this will extend life for several months on the average, but some may achieve surprising results of regression of disease and even years. The cost is rather high, over $90k for the treatment.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Prostate Cancer Genetic Testing - Is it real or is it boutique lab work?

January 20, 2009

Clarient Launches Gene Expression Test for Prostate Cancer | www.medcompare.com

Genetic testing for clinically significant prostate cancer is vital to allow clinicians to treat patients.  This appears to be a step in the right direction, although it does not seem this will have a major impact for the majority of cases. The study represents only a small subgroup of patients that may have some benefit from this new molecular biology test.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Intermittent hormonal therapy for Prostate Cancer: Is it here yet?

January 2, 2009

Finnish Multicenter Study Comparing Intermittent To Continuous Androgen Deprivation For Advanced Prostate Cancer | www.medicalnewstoday.com

prostate cancer, hormonal therapy, intermittent treatemtent

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Prostate cancer DNA vaccine trial - a necessary step

December 29, 2008

Approval From The Swedish Medical Products Agency To Start A Clinical Trial Using A Xenogenic PSA DNA Vaccine | www.medicalnewstoday.com

prostate cancer, vaccine, dna

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Robotic Prostatectomy ?Too soon to tell?

May 29, 2008

Mixed Outcomes in Laparoscopy for Prostates | www.nytimes.com

The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer.  There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities.  However, the data does not show a clinical advantage in cancer cure or clinically significant improvement in cancer control.  Much more data is needed over a longer period of time.  The article does not mention surgeon experience, i.e. those who have done many robotic prostatectomies vs. a surgeon with a limited experience.  Nor does the article mention post operative complications such as preservation of erectile function and continence control.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Novel immunotherapy for prostate cancer

April 16, 2008

Cell Genesys Announces Encouraging Results from Phase 1/2 Trial of GVAX Immunotherapy for Prostate Cancer in Recurrent Disease | www.pipelinereview.com

Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease.  It also opens the door to other therapeutic interventions.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Wet pajamas must be back in style???

December 6, 2007

Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) | www.fda.gov

The FDA has made the nasal spray formulation of DDAVP be withdrawn due to potential significant side effects of life threatening hyponatremia (low blood sodium) as well as potential seizures. I an unable to identify the data from this announcement as to why this occured. DDAVP nasal spray has been used for over 10 years for the treatment of primary noctural eneuresis (bedwetting) with good success.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

?Role of IMC-A12 for metastatic prostate cancer

September 3, 2007

Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment | www.pipelinereview.com

This immunotherapy is based upon Insulin-like growth factor which may be expressed in prostate cancer.  There is not much data on this.  The study is very limited, 30 patients, and must not have received any chemotherapy prior to enrolling.  The sponsor is IM Clone.  I do not know what research institutions will be enrolling patients.  A limited investigation is warranted, but the data will be crucial if to go on to a Phase III trial

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Too little too late

September 1, 2006

New Procedure Helps Stop Urinary Incontinence | www.medicalnewstoday.com

The TVT procedure is about 8-10 years old.  We are on the verge of the third generation of this device.  This particular procedure is somewhat antiquated and has higher risks than the newer versions.

Mitchell BambergerAttending PhysicianTRICOUNTY MEDICAL ASSOCIATES INC What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Trospium struggles in the face of a fast market

September 1, 2006

Trospium Chloride Meets Primary and Secondary Endpoints in Phase 3 Trial | www.ptcommunity.com

Trospium Chloride (Sanctura) came out in Dec 2004 along with Vesicare (Astellas Pharm) and Enablex (Novartis) all with a few weeks of each other. Sanctura has struggled mainly because it came out as a twice/day drug while the others were once/day.  The clinical efficacy and side effect profile are all relatively the same. I see no major advantage of this newer formulation only in that it is now once/day.  It is in last place in market share and unless can show significant benefits, will probably remain so.

Page : 12Next1 to 10 of 12

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News